Axial Spondyloarthritis (axSpA) - Epidemiology Forecast - 2032

This ‘Axial Spondyloarthritis (AxSpA) - Epidemiology Forecast-2032' report delivers an in-depth understanding of the axSpA, historical and forecasted epidemiology as well as the axSpA trends in the United States.

Axial Spondyloarthritis (axSpA) Disease Understanding

Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition that consists of two subsets, which clinically have been defined as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Nr-axSpA is characterized by the absence of definitive x-ray evidence of structural damage to the sacroiliac (SI) joint by plain x-ray. Since the SI joint x-ray interpretation is subjective, the distinction between nr-axSpA and AS is not absolute. Sacroiliitis (inflammation of the SI joint) and inflammation of the spine are predominant features of axSpA; hence patients typically present with inflammatory back pain. Other manifestations, such as enthesitis, dactylitis, peripheral arthritis, anterior uveitis, psoriasis, and inflammatory bowel disease, are common. Over time many patients with nr-axSpA develop the structural damage of sacroiliac joints, ultimately progressing to AS; however, some nr-axSpA patients will never advance to this stage. The clinical manifestations for axSpA and nr-axSpA are similar to the patients' disease burden experience.

Patients with axSpA commonly complain of back pain that starts before 45 years of age. Back pain's characteristic features include chronicity (>3 months), insidious onset, improvement with exercise, an occurrence at night with improvement upon waking, and no rest. Inflammatory back pain (IBP) criteria are essential in screening for axSpA. Among at-risk patients, the sensitivity of IBP (approximately 70-95%) for axSpA is relatively high (back pain >3 months with onset age).

Axial Spondyloarthritis (axSpA) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Axial Spondyloarthritis, Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis scenario in the 7MM countries covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan Axial Spondyloarthritis (axSpA)

Detailed Epidemiology Segmentation

• The total prevalent population of axSpA in the 7MM was 3,981,346. These cases are anticipated to increase in during the forecast period [2022-2032].
• The highest prevalent cases of axSpA were accounted by the US in 2021, making up to 2,217,315 cases, while the EU5 countries accounted for 1,751,778 cases in the same year.
• Among the different types of genes in axSpA, i.e., HLA-B27, and Others (ERAP 1, IL-12, IL-17, and IL-23), the former accounts for a higher number of diagnosed prevalent cases of axSpA (789622) in the EU-5 in 2021.
• As per the analysis, a higher percentage of diagnosed prevalence was observed in males in AS, in comparison to females, in all the 7MM countries
• In 2021, 70.90% of the total diagnosed prevalent population of Ankylosing spondylitis (AS) in Japan were male, which is equivalent to 2,903 cases. In comparison, for females, 1,192 cases were observed in 2021.
• Japan had 5,000 diagnosed prevalent cases for axSpA in 2021, being the lowest of all other countries in 7MM.

Scope of the Report

• The report covers the descriptive overview of AXSPA, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the historical and forecasted patient pool covering the United States.
• The report assesses the disease risk and burden and highlights the unmet needs of AXSPA.
• The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM countries by Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis.

Report Highlights

• 11-Year Forecast of axSpA
• 7MM Coverage
• Total Prevalent Cases of Axial Spondyloarthritis
• Total Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
• Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis

Key Questions Answered

• What are the disease risk, and burden of axSpA?
• What is the historical axSpA patient pool in the 7MM countries?
• What would be the forecasted patient pool of axSpA at the 7MM level?
• What will be the growth opportunities across the 7MM countries with respect to the patient population pertaining to axSpA?
• Out of the above-mentioned countries, which country would have the highest prevalent population of axSpA during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM countries during the forecast period (2022-2032)?

Reasons to Buy

The AXSPA report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM axSpA epidemiology forecast.
• The axSpA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The axSpA epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032